Pharmacogenomics in type 2 diabetes: Oral antidiabetic drugs

Geltrude Mingrone, M. A. Daniels, C. Kan, D. M. Willmes, K. Ismail, F. Pistrosch, D. Hopkins, S. R. Bornstein, A. L. Birkenfeld

Risultato della ricerca: Contributo in rivistaArticolo in rivista

9 Citazioni (Scopus)


Type 2 diabetes mellitus (T2DM) is a fast progressing disease reaching pandemic proportions. T2DM is specifically harmful because of its severe secondary complications. In the course of the disease, most patients require treatment with oral antidiabetic drugs (OADs), for which a relatively large number of different options are available. The growing number of individuals affected by T2DM as well as marked interindividual differences in the response to treatment call for individualized therapeutic regimens that can maximize treatment efficacy and thus reduce side effects and costs. A large number of genetic polymorphisms have been described affecting the response to treatment with OADs; in this review, we summarize the most recent advances in this area of research. Extensive evidence exists for polymorphisms affecting pharmacokinetics and pharmacodynamics of biguanides and sulfonylureas. Data on incretin-based medications as well as the new class of sodium/glucose cotransporter 2 (SGLT2) inhibitors are just starting to emerge. With diabetes being a known comorbidity of several psychiatric disorders, we also review genetic polymorphisms possibly responsible for a common treatment response in both conditions. For all drug classes reviewed here, large prospective trials are necessary in order to consolidate the existing evidence and derive treatment schemes based on individual genetic traits.
Lingua originaleEnglish
pagine (da-a)399-410
Numero di pagine12
RivistaPharmacogenomics Journal
Stato di pubblicazionePubblicato - 2016


  • Genetics
  • Molecular Medicine
  • Pharmacology

Fingerprint Entra nei temi di ricerca di 'Pharmacogenomics in type 2 diabetes: Oral antidiabetic drugs'. Insieme formano una fingerprint unica.

Cita questo